The goal of creating synthetic cells is not to replace nature, but to learn more deeply about biology and reengineer it to ...

In a paper published in Proceedings of the National Academy of Sciences, researchers from Technion and Tel Aviv University ...

Savings plans must provide future income projections based only on your current balance. That could tempt younger workers to ...

In this post, we will show you how to create email templates in the new Outlook app for Windows 11. Creating email or message templates in Microsoft Outlook (classic) involved manually composing an ...

Create subscription-1 resources Use az sign-in to sign-in to subscription-1 with a user account with permissions to create a resource group, a virtual network, and an SPN in the Microsoft Entra ID ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

The Northwest’s only commercial nuclear power plant, the Columbia Generating Station, was manually shut down early Thursday morning due to a mechanical problem. Energy Northwest workers shut the plant ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...